The FDA accepts Sanofi's (SNY +1.85%) once-daily lixisenatide diabetes drug for review; the...

|About: Sanofi (SNY)|By:, SA News Editor

The FDA accepts Sanofi's (SNY +1.85%) once-daily lixisenatide diabetes drug for review; the company expects to launch the treatment in the EU at the end of Q1 after receiving approval earlier this month. (PR)